Global Exportin 1 麻豆原创 Research Report 2023

Publication ID:

PB501234645

Publication Date:

January 12, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) 鈥� Exportin 1 (XPO1) or chromosomal maintenance 1 (CRM1) is a eukaryotic protein. It mediates the nuclear export of cellular proteins bearing a leucine-rich nuclear export signal (NES) and of RNAs. In association with RANBP3, it binds cooperatively to the NES on its target protein and to the GTPase RAN in its active Ran-GTP. Docking of this complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins. It is involved in U3 snoRNA transport from Cajal bodies to nucleoli. The molecules developed by companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 3, 1, 3 and 1 respectively.
Highlights
The global Exportin 1 market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Exportin 1 is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Exportin 1 is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Exportin 1 include Biogen Inc, CanBas Co Ltd, Jiangsu Carephar Pharmaceutical Co Ltd, Karyopharm Therapeutics Inc, Oita University Institute of Advanced Medicine Inc and Wigen Biomedicine Technology (Shanghai) Co Ltd, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Exportin 1, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Exportin 1.
The Exportin 1 market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Exportin 1 market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Exportin 1 manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Biogen Inc
CanBas Co Ltd
Jiangsu Carephar Pharmaceutical Co Ltd
Karyopharm Therapeutics Inc
Oita University Institute of Advanced Medicine Inc
Wigen Biomedicine Technology (Shanghai) Co Ltd
Segment by Type
Chromosome Region Maintenance 1 Protein Homolog
XPO1
Segment by Application
Oncology
Central Nervous System
Immunology
Genetic Disorders
Infectious Disease
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Exportin 1 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Exportin 1 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Exportin 1 麻豆原创 Overview
1.1 Product Overview and Scope of Exportin 1
1.2 Exportin 1 Segment by Type
1.2.1 Global Exportin 1 麻豆原创 Value Comparison by Type (2023-2029)
1.2.2 Chromosome Region Maintenance 1 Protein Homolog
1.2.3 XPO1
1.3 Exportin 1 Segment by Application
1.3.1 Global Exportin 1 麻豆原创 Value by Application: (2023-2029)
1.3.2 Oncology
1.3.3 Central Nervous System
1.3.4 Immunology
1.3.5 Genetic Disorders
1.3.6 Infectious Disease
1.4 Global Exportin 1 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Exportin 1 Revenue 2018-2029
1.4.2 Global Exportin 1 Sales 2018-2029
1.4.3 Global Exportin 1 麻豆原创 Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Exportin 1 麻豆原创 Competition by Manufacturers
2.1 Global Exportin 1 Sales 麻豆原创 Share by Manufacturers (2018-2023)
2.2 Global Exportin 1 Revenue 麻豆原创 Share by Manufacturers (2018-2023)
2.3 Global Exportin 1 Average Price by Manufacturers (2018-2023)
2.4 Global Exportin 1 Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Exportin 1, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Exportin 1, Product Type & Application
2.7 Exportin 1 麻豆原创 Competitive Situation and Trends
2.7.1 Exportin 1 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Exportin 1 Players 麻豆原创 Share by Revenue
2.7.3 Global Exportin 1 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Exportin 1 Retrospective 麻豆原创 Scenario by Region
3.1 Global Exportin 1 麻豆原创 Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Exportin 1 Global Exportin 1 Sales by Region: 2018-2029
3.2.1 Global Exportin 1 Sales by Region: 2018-2023
3.2.2 Global Exportin 1 Sales by Region: 2024-2029
3.3 Global Exportin 1 Global Exportin 1 Revenue by Region: 2018-2029
3.3.1 Global Exportin 1 Revenue by Region: 2018-2023
3.3.2 Global Exportin 1 Revenue by Region: 2024-2029
3.4 North America Exportin 1 麻豆原创 Facts & Figures by Country
3.4.1 North America Exportin 1 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Exportin 1 Sales by Country (2018-2029)
3.4.3 North America Exportin 1 Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Exportin 1 麻豆原创 Facts & Figures by Country
3.5.1 Europe Exportin 1 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Exportin 1 Sales by Country (2018-2029)
3.5.3 Europe Exportin 1 Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Exportin 1 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Exportin 1 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Exportin 1 Sales by Country (2018-2029)
3.6.3 Asia Pacific Exportin 1 Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Exportin 1 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Exportin 1 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Exportin 1 Sales by Country (2018-2029)
3.7.3 Latin America Exportin 1 Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Exportin 1 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Exportin 1 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Exportin 1 Sales by Country (2018-2029)
3.8.3 Middle East and Africa Exportin 1 Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Exportin 1 Sales by Type (2018-2029)
4.1.1 Global Exportin 1 Sales by Type (2018-2023)
4.1.2 Global Exportin 1 Sales by Type (2024-2029)
4.1.3 Global Exportin 1 Sales 麻豆原创 Share by Type (2018-2029)
4.2 Global Exportin 1 Revenue by Type (2018-2029)
4.2.1 Global Exportin 1 Revenue by Type (2018-2023)
4.2.2 Global Exportin 1 Revenue by Type (2024-2029)
4.2.3 Global Exportin 1 Revenue 麻豆原创 Share by Type (2018-2029)
4.3 Global Exportin 1 Price by Type (2018-2029)
5 Segment by Application
5.1 Global Exportin 1 Sales by Application (2018-2029)
5.1.1 Global Exportin 1 Sales by Application (2018-2023)
5.1.2 Global Exportin 1 Sales by Application (2024-2029)
5.1.3 Global Exportin 1 Sales 麻豆原创 Share by Application (2018-2029)
5.2 Global Exportin 1 Revenue by Application (2018-2029)
5.2.1 Global Exportin 1 Revenue by Application (2018-2023)
5.2.2 Global Exportin 1 Revenue by Application (2024-2029)
5.2.3 Global Exportin 1 Revenue 麻豆原创 Share by Application (2018-2029)
5.3 Global Exportin 1 Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Biogen Inc
6.1.1 Biogen Inc Corporation Information
6.1.2 Biogen Inc Description and Business Overview
6.1.3 Biogen Inc Exportin 1 Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Biogen Inc Exportin 1 Product Portfolio
6.1.5 Biogen Inc Recent Developments/Updates
6.2 CanBas Co Ltd
6.2.1 CanBas Co Ltd Corporation Information
6.2.2 CanBas Co Ltd Description and Business Overview
6.2.3 CanBas Co Ltd Exportin 1 Sales, Revenue and Gross Margin (2018-2023)
6.2.4 CanBas Co Ltd Exportin 1 Product Portfolio
6.2.5 CanBas Co Ltd Recent Developments/Updates
6.3 Jiangsu Carephar Pharmaceutical Co Ltd
6.3.1 Jiangsu Carephar Pharmaceutical Co Ltd Corporation Information
6.3.2 Jiangsu Carephar Pharmaceutical Co Ltd Description and Business Overview
6.3.3 Jiangsu Carephar Pharmaceutical Co Ltd Exportin 1 Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Jiangsu Carephar Pharmaceutical Co Ltd Exportin 1 Product Portfolio
6.3.5 Jiangsu Carephar Pharmaceutical Co Ltd Recent Developments/Updates
6.4 Karyopharm Therapeutics Inc
6.4.1 Karyopharm Therapeutics Inc Corporation Information
6.4.2 Karyopharm Therapeutics Inc Description and Business Overview
6.4.3 Karyopharm Therapeutics Inc Exportin 1 Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Karyopharm Therapeutics Inc Exportin 1 Product Portfolio
6.4.5 Karyopharm Therapeutics Inc Recent Developments/Updates
6.5 Oita University Institute of Advanced Medicine Inc
6.5.1 Oita University Institute of Advanced Medicine Inc Corporation Information
6.5.2 Oita University Institute of Advanced Medicine Inc Description and Business Overview
6.5.3 Oita University Institute of Advanced Medicine Inc Exportin 1 Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Oita University Institute of Advanced Medicine Inc Exportin 1 Product Portfolio
6.5.5 Oita University Institute of Advanced Medicine Inc Recent Developments/Updates
6.6 Wigen Biomedicine Technology (Shanghai) Co Ltd
6.6.1 Wigen Biomedicine Technology (Shanghai) Co Ltd Corporation Information
6.6.2 Wigen Biomedicine Technology (Shanghai) Co Ltd Description and Business Overview
6.6.3 Wigen Biomedicine Technology (Shanghai) Co Ltd Exportin 1 Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Wigen Biomedicine Technology (Shanghai) Co Ltd Exportin 1 Product Portfolio
6.6.5 Wigen Biomedicine Technology (Shanghai) Co Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Exportin 1 Industry Chain Analysis
7.2 Exportin 1 Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Exportin 1 Production Mode & Process
7.4 Exportin 1 Sales and 麻豆原创ing
7.4.1 Exportin 1 Sales Channels
7.4.2 Exportin 1 Distributors
7.5 Exportin 1 Customers
8 Exportin 1 麻豆原创 Dynamics
8.1 Exportin 1 Industry Trends
8.2 Exportin 1 麻豆原创 Drivers
8.3 Exportin 1 麻豆原创 Challenges
8.4 Exportin 1 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Biogen Inc
CanBas Co Ltd
Jiangsu Carephar Pharmaceutical Co Ltd
Karyopharm Therapeutics Inc
Oita University Institute of Advanced Medicine Inc
Wigen Biomedicine Technology (Shanghai) Co Ltd

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.